Protein power: new study tests Muscle-Building meals for COPD patients
NCT ID NCT01734473
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether adding casein protein and leucine (an amino acid) to meals could help people with COPD and healthy older adults build more muscle. Weight loss and muscle loss are common in COPD and can make the disease worse. Researchers tested different meal combinations in 36 participants to see which best boosted protein building in the body.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
36 people
The number who actually took part.
- Started
-
Nov 2012
- Finished
-
May 2015
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria COPD subjects: * Ability to walk, sit down and stand up independently * Age 45 years or older * Ability to lie in supine or elevated position for 5.5 hours * Diagnosis of moderate to very severe chronic airflow limitation and compliant to the following criteria: Forced Expiratory Volume(FEV1)/Forced Vital Capacity (FVC) \< 0.70 and FEV1 \< 70% of reference FEV1 * Clinically stable condition and not suffering from a respiratory tract infection or exacerbation of their disease (defined as a combination of increased cough, sputum purulence, shortness of breath, systemic symptoms such as fever, and a decrease in FEV1 \> 10% compared with values when clinically stable in the preceding year) at least 4 weeks prior to the first test day * Shortness of breath on exertion * Willingness and ability to comply with the protocol, including: * Adhering to fasting state from 10 pm ± 2h onwards the day prior to each study visit Inclusion criteria healthy control subjects: * Healthy male or female according to the investigator's or appointed staff's judgment * Ability to walk, sit down and stand up independently * Age 45 years or older * Ability to lay in supine or elevated position for 5.5 hours * No diagnosis of chronic airflow limitation and compliant to the following criteria: FEV1/FVC \> 0.70 and FEV1 ≥ 80% of reference FEV1 * Willingness and ability to comply with the protocol, including: * Adhering to fasting state from 10 pm ± 2h onwards the day prior to each study visit Exclusion Criteria all subjects: * Any condition that may interfere with the definition 'healthy subject' according to the investigator's judgment (for healthy control group only) * Established diagnosis of malignancy * Established diagnosis of Insulin Dependent Diabetes Mellitus * History of untreated metabolic diseases including hepatic or renal disorder * Presence of acute illness or metabolically unstable chronic illness * Recent myocardial infarction (less than 1 year) * Any other condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient * BMI of \< 18.5 or ≥ 35 kg/m2 * Dietary or lifestyle characteristics: * Use of protein or amino acid containing nutritional supplements within 5 days of first test day * Current alcohol or drug abuse * Indications related to interaction with study products: * Known allergy to milk or milk products * Use of long-term oral corticosteroids or short course of oral corticosteroids 4 weeks preceding first test day * Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements * (Possible) pregnancy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Texas A&M University
College Station, Texas, 77843, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an inhaler boost heart pumping in COPD patients?
- Can Device-Preserved donor lungs boost transplant success?
- Tiny One-Way valves for emphysema under close watch in japan
- Is RSV a hidden driver of severe COPD attacks?
- Can Mountain-Air rehab loosen stiff COPD airways?
- Can a breath of extra oxygen boost lung rehab?